Business Wire

General Counsels Accelerate Technology Adoption to Tackle Compliance Pressures

Share

General counsels (GCs) across the globe are rapidly adopting technology, including generative artificial intelligence (AI), to optimize legal operations and stay on top of growing compliance pressures. This is according to new research conducted among 350 GCs and legal compliance officers across key global markets commissioned by CSC, the world’s leading provider of global business administration and compliance solutions.

CSC’s study1, General Counsel Barometer 2025, reveals that upgrading technology and automation sits firmly at the top of legal departments’ strategic priorities for the year ahead. The majority of legal departments (97%) are already using generative AI, with 49% saying the technology is significantly helping their legal teams.

The most widely reported benefits of AI tools include handling larger volumes of work more efficiently (66%), improving processing times (40%), and enhancing fraud detection and risk management (41%)—highlighting technology’s role in easing pressure on stretched legal teams and strengthening operational resilience.

“Even a year ago, everyone was interested in AI, but at the same time, were still standing on the sidelines and asking how trustworthy it was,” said Thijs van Ingen, global head of Corporate Solutions at CSC. “We’re now seeing real added value and productivity gains, particularly in complex areas like M&A. The shift towards tech-enabled partners shows GCs are acting decisively to modernize their departments in the face of mounting operational pressure.”

Yet confidence is tempered by caution. 72% of GCs have implemented internal governance policies to manage AI use, citing fraud, data privacy, and third-party risks as their top concerns.

“AI is here to stay—but responsible use is key,” added Ian McConnel, chief legal officer at CSC. “GCs are rightly focused on governance, accuracy, and data integrity. As legal teams evolve, they’re becoming leaders in embedding safe, effective AI into core business processes—but success will depend on ensuring the data sets behind these tools are both accurate and robust.”

These shifts are happening against a backdrop of rising compliance demands. Nearly three-quarters (72%) of GCs expect legal and regulatory costs to increase in the next three years, yet only 27% say they feel “very prepared” for new requirements such as expanded beneficial ownership disclosures. The changing regulatory landscape was cited as the number one risk to legal operations in 2025.

As well as embracing technology, nearly six-in-10 (58%) GCs report increased outsourcing to specialist partners—a move driven by resourcing constraints and the need for scalable, tech-enabled support across multiple jurisdictions.

“As organizations pursue global expansion, GCs are leading the charge,” adds van Ingen. “By embedding smarter systems and forming strategic partnerships, GCs are playing a pivotal role in helping their organizations manage risk, drive efficiency, and scale legal operations globally. This marks a defining shift in the role of legal function, where GCs are guiding their organizations into a more agile, tech-enabled future.”

To receive a copy of CSC’s General Counsel Barometer 2025 report, please contact Hassan Ali at cscteam@citigatedewerogerson.com.

1CSC, in partnership with Pure Profile, surveyed 350 general counsels and legal compliance officers in the Americas, Europe including UK, and Asia Pacific in 2025. Survey respondents were drawn from a range of industry sectors including communications, banking and financial services, healthcare, insurance, law, and real estate.

About CSC

CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250519574808/en/

Contacts

For more information:
Citigate Dewe Rogerson
Hassan Ali | Amber Liu
cscteam@citigatedewerogerson.com

CSC
Laura Crozier
PR Manager
laura.crozier@cscglobal.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54254846&newsitemid=20250519574808&lan=en-US&anc
hor=CSC+News+Room&index=1&md5=cec24fbd31b89e9857a98470e811e507

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in

You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release

Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc

CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release

Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale

Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release

In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha

FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release

Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye